Search

Saad Usmani, MD, has been named Chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center.

… Wednesday, December 1, 2021 Saad Usmani, MD, has been named Chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center (MSK). He joins MSK from the Levine Cancer Center in North Carolina and succeeds C. Ola Landgren, MD, PhD, who previously served in this role for six years. Dr. Usmani is

Along with Valentine's Day, February marks American Heart Month. MSK’s Vice Chair of Radiation Oncology, Dr Oren Cahlon talks on how his team are making radiation-induced heart disease “a thing of the past” for our breast cancer patients.

… Tuesday, February 13, 2018

Learn how intermittent fasting is being explored by researchers for possible use in cancer treatment and prevention, including breast cancer.

… Friday, October 9, 2020 Summary An MSK expert explains what is known about the weight-loss technique called intermittent fasting as a tool against breast cancer . Intermittent fasting is one of the most talked-about topics among people looking to lose weight and improve their overall health. The basic

The Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK) at Memorial Sloan Kettering Cancer Center (MSK) today announced The Pat and Ian Cook Doctoral Program in Cancer Engineering, made possible by a generous gift of $15 million from Pat and Ian Cook.

… Tuesday, August 22, 2023 The Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK) at Memorial Sloan Kettering Cancer Center (MSK) today announced The Pat and Ian Cook Doctoral Program in Cancer Engineering, made possible by a generous gift of $15 million from Pat and Ian Cook. This visionary

The experimental drug selumetinib is the first targeted therapy to demonstrate significant clinical benefit for patients with metastatic uveal melanoma, according to new Memorial Sloan Kettering Cancer Center research presented at the 49th annual meeting of the American Society of Clinical Oncology.

… Saturday, June 1, 2013 The experimental drug selumetinib is the first targeted therapy to demonstrate significant clinical benefit for patients with metastatic uveal melanoma , according to new Memorial Sloan Kettering Cancer Center research presented on Saturday, June 1, at the 49th annual meeting of

MSK researchers used the genome-editing tool CRISPR to create more potent chimeric antigen receptor (CAR) T cells that don't tire as easily when attacking cancer cells. The unexpected findings were published in the journal Nature on February 22 and underscore the potential of genome editing to advance immunotherapy for cancer.

… Wednesday, February 22, 2017 Researchers from Memorial Sloan Kettering Cancer Center (MSK) have harnessed the power of CRISPR/Cas9 to create more-potent chimeric antigen receptor (CAR) T cells that enhance tumor rejection in mice. The unexpected findings, published in Nature on February 22, uncover facets

On November 10, 2025, hundreds gathered in the Mortimer B. Zuckerman Research Center for the “MSK Innovation with Lasting Impact Summit: Entrepreneurship & Innovation at MSK,” at an event that brought together laboratory and clinical researchers, digital health innovators, healthcare executives, and investors.

… Thursday, December 18, 2025 On November 10, 2025, hundreds gathered in the Mortimer B. Zuckerman Research Center for the “MSK Innovation with Lasting Impact Summit: Entrepreneurship & Innovation at MSK,” at an event that brought together laboratory and clinical researchers, digital health innovators,

Learn about MSK’s active surveillance program for papillary thyroid cancer, which allows many people to avoid unnecessary surgery and the risks that come with it.

… Wednesday, November 13, 2024 Advances in cancer detection have saved many lives, but they have a serious drawback: Some cancers are being overdiagnosed, which can lead to the unnecessary treatment of tumors that would have posed no threat if left alone.  One cancer that may not need treatment right away

Obtenga información sobre el programa de observación activa de MSK para el cáncer de tiroides papilar, que permite a muchas personas evitar cirugías innecesarias y los riesgos que estas tienen.

… Wednesday, November 13, 2024 Los avances en la detección del cáncer han salvado muchas vidas, pero tienen una desventaja importante: algunos casos de cáncer se están sobrediagnosticando, lo que puede llevar a tratar innecesariamente tumores que no habrían representado una amenaza si se hubieran dejado

Though questions remain about how best to use genetic testing for cancer, the trend is toward more inclusive criteria.

… Tuesday, October 22, 2019 Summary Clinical genetics experts see value in testing more women for BRCA mutations. These days, anyone with an interest and about $100 can spit into a tube, mail it to a genetic testing company, and get back details on their DNA. This is known to some as recreational genomics